ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Scientist I at Generate:Biomedicines - ApplyBlast

Scientist I

Generate:Biomedicines

13 days ago

4.0 on Glassdoor

Somerville, Massachusetts, United States

Onsite

Full Time

Junior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Generate Biomedicines is seeking a Scientist I with a strong background in immunology and hands-on expertise with human primary immune cells to support the development of protein-based therapeutics for immune-mediated diseases. This laboratory-focused role involves independently planning and executing in vitro experiments, analyzing results, and generating data packages to inform project decisions. The position offers the opportunity to apply mechanistic immunology to the development of AI-enabled biologic therapeutics within a multidisciplinary team.

Responsibilities

Design and execute cell-based assays using human primary immune cells
Develop and optimize T cell functional assays and co-culture systems
Analyze and interpret reproducible data to support project decisions

Skills

Qualifications

Ph.D. in immunology, cell biology, or a related fieldmaster’s degree in a related fieldbachelor’s degree in a related field

About Generate:Biomedicines

generatebiomedicines.com

Headquarters

Somerville, Massachusetts, United States

Company Size

201-500 employees

View Profile

Generate:Biomedicines is a therapeutics company that combines machine learning, computational biology, and biological engineering to design and develop precision protein medicines and antibodies. Using generative AI and lab-driven engineering, the company builds targeted biologics and epitope-focused candidates, advancing a pipeline from discovery through clinical development. Its clinical-stage programs include GB-0895, a long‑acting anti‑TSLP antibody progressing to global Phase 3 studies, and the company has recently completed an initial public offering. Generate was incubated by Flagship Pioneering and emphasizes platform-driven discovery to accelerate novel biologic therapeutics.